-
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. e-ruderman@northwestern.edu
Abatacept (CTLA4-Ig) is a novel fusion protein designed to modulate the T cell co-stimulatory signal mediated through the CD28-CD80/86 pathway. Clinical trials have provided preliminary evidence of the efficacy of this compound in the treatment of rheumatoid arthritis. This review describes the molecular and biologic bases for the use of abatacept in rheumatoid arthritis and summarizes the current clinical data on its safety and effectiveness in this disease.
PMID: 15833145 [PubMed - indexed for MEDLINE]
-
Cited by 3 PubMed Central articles
-
ReviewRecent developments in the immunobiology of rheumatoid arthritis.
Andersson AK, Li C, Brennan FM.
Arthritis Res Ther. 2008; 10(2):204. Epub 2008 Mar 14.
[Arthritis Res Ther. 2008]
-
Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation.
Grassi F, Tell G, Robbie-Ryan M, Gao Y, Terauchi M, Yang X, Romanello M, Jones DP, Weitzmann MN, Pacifici R.
Proc Natl Acad Sci U S A. 2007 Sep 18; 104(38):15087-92. Epub 2007 Sep 11.
[Proc Natl Acad Sci U S A. 2007]
-
Arthritis suppression by NADPH activation operates through an interferon-beta pathway.
Olofsson P, Nerstedt A, Hultqvist M, Nilsson EC, Andersson S, Bergelin A, Holmdahl R.
BMC Biol. 2007 May 9; 5:19. Epub 2007 May 9.
[BMC Biol. 2007]